Veru submitted EUA to U.S. FDA for Sabizabulin, its anti-Inflammatory drug candidate for hospitalized COVID-19 patients
On Jun. 7, 2022, Veru, a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral…
-
-
Montefiore-Einstein Scientists lead two trials of leronlimab for treatment of severe lung inflammation in COVID-19 patients
On May 21, 2020, Montefiore Health System and Albert Einstein College of Medicine were the first sites in…
-
New study from pandemic epicenter described severe COVID-19 response in children
On May 19, 2020, the Albert Einstein College of Medicine reported that while most children infected with the…
-
3M and Ford begin shipping newly designed powered air-purifying respirators for health care workers fighting COVID-19
On May 6, 2020, 3M and Ford announced that newly designed powered air-purifying respirators (PAPRs), developed are on…
-
Athersys Announces Commencement of Patient Enrollment in the MACOVIA Study, a Pivotal Phase 2/3 Trial Evaluating MultiStem® Cell Therapy for COVID-19 Induced ARDS
On May 5, 2020, Athersys announced that the first patients have been enrolled in Athersys’ pivotal Phase 2/3…
-
Athersys announced commencement of patient enrollment in MACOVIA Study, a pivotal phase 2/3 trial evaluating MultiStem cell therapy for COVID-19 induced ARDS
On May 5, 2020, Athersys announced the first patients have been enrolled in Athersys’ pivotal Phase 2/3 study…
-
Windtree announced first patient enrolled in AEROSURF bridging study for treatment of Respiratory Distress Syndrome
On Apr. 29, 2020, Windtree Therapeutics announced it has enrolled the first patient into its AEROSURF phase 2b…
-
Mesoblast reported 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory distress syndrome
On Apr. 24, 2020, Mesoblast announced an 83% survival in ventilator-dependent COVID-19 patients (10/12) with moderate/severe acute respiratory…
